Chemotherapy regimens containing azacitidine and mitoxantrone liposome for angioimmunoblastic T-cell lymphoma:report of 1 case and review of literature
10.3760/cma.j.cn115356-20231109-00069
- VernacularTitle:含阿扎胞苷及米托蒽醌脂质体化疗方案治疗血管免疫母细胞性T细胞淋巴瘤1例并文献复习
- Author:
Xiaoyi WANG
1
;
Jie YU
;
Fumeng YAN
;
Xiuzhi DENG
;
Yili WANG
Author Information
1. 威海市立医院血液科，威海 264200
- Keywords:
Lymphoma,T-cell;
Angioimmunoblastic T-cell lymphoma;
Azacitidine;
Mitoxantrone liposome;
Treatment
- From:
Journal of Leukemia & Lymphoma
2024;33(9):540-542
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the treatment outcome of chemotherapy regimens containing azacitidine and mitoxantrone liposome in the treatment of angioimmunoblastic T-cell lymphoma (AITL).Methods:The clinical data of 1 AITL patient with severe clinical symptoms admitted to Weihai Municipal Hospital in July 2021 were retrospectively analyzed, and the relevant literatures were reviewed.Results:The 74-year-old male patient was presented with the manifestations of rash, lymph node enlargement, bloating and fever. He was pathologically diagnosed as AITL by lymph node biopsy. In the early stage of treatment, due to severe clinical symptoms and poor therapeutic effect, the treatment regimens were constantly adjusted. CHOPE, etoposide + chidamide + thalidomide +dexamethasone + cyclosporine, brentuximab vedotin + bendamustine + dexamethasone + cyclosporine + thalidomide +chidamide regimens were used successively, and the disease progressed after short-term complete remission. Finally complete remission was obtained again after a multi-drug combination regimens containing azacitidine and mitoxantrone liposome, following the maintenance treatment of azacitidine combined with chidamide, and the disease condition of the patient remained stable.Conclusions:The chemotherapy regimens containing azacitidine and mitoxantrone liposome can achieve a good therapeutic effect for relapsed/refractory AITL.
